Vir Biotechnology Cash Flow Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	2018 - 2017
Net Income	-539.44	-615.06	515.84	528.58	-298.67	-174.68	Upgrade
Depreciation & Amortization	25.26	27.11	15.49	11.98	8.81	4.52	Upgrade
Share-Based Compensation	109.59	111.32	102.08	83.78	27.6	8.72	Upgrade
Other Operating Activities	-357.81	-302.15	1,030	-671.94	71.31	31.82	Upgrade
Operating Cash Flow	-762.39	-778.79	1,663	-47.59	-190.94	-129.63	Upgrade
Capital Expenditures	-16.05	-21.57	-68.01	-21.82	-6.55	-8.94	Upgrade
Change in Investments	111.02	186.2	-1,125.46	-119	-3.49	-247.22	Upgrade
Other Investing Activities	-	-	-	-	0.18	-	Upgrade
Investing Cash Flow	94.97	164.63	-1,193.46	-140.81	-9.86	-256.16	Upgrade
Share Issuance / Repurchase	5.68	7.77	36.22	100.59	533.97	127.54	Upgrade
Debt Issued / Paid	-0.29	-0.29	-0.26	-0.26	-0.25	4.37	Upgrade
Other Financing Activities	-0.1	-	-1.2	-	-4.25	317.34	Upgrade
Financing Cash Flow	5.29	7.48	34.76	100.33	529.47	449.24	Upgrade
Net Cash Flow	-662.14	-606.68	504.55	-88.07	328.67	63.45	Upgrade
Free Cash Flow	-778.44	-800.36	1,595	-69.41	-197.49	-138.57	Upgrade
Free Cash Flow Margin	-977.95%	-928.71%	98.73%	-6.34%	-258.60%	-1712.67%	Upgrade
Free Cash Flow Per Share	-5.75	-5.97	12.03	-0.53	-1.66	-4.57	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).